Oxford BioDynamics PLC Grant of Canadian patent for EpiSwitch platform (0755V)
19 July 2018 - 4:00PM
UK Regulatory
TIDMOBD
RNS Number : 0755V
Oxford BioDynamics PLC
19 July 2018
19 July 2018
Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the
"Group")
Oxford BioDynamics announces grant of Canadian patent for its
proprietary technology platform, EpiSwitch(TM)
Oxford BioDynamics Plc ("OBD" or the "Company"), a biotechnology
company focused on the discovery and development of epigenetic
biomarkers based on regulatory genome architecture, for use within
the pharmaceutical and biotechnology industry, today announces the
grant of a key patent by the Canadian Intellectual Property Office
covering EpiSwitch(TM), the Company's novel technology
platform.
The Canadian patent, number 2642331, covers OBD's proprietary
EpiSwitch(TM) technology designs for high resolution discovery and
monitoring of regulatory conditional chromosome conformation
signatures, as part of the regulatory architecture of the genome.
As a biomarker modality, chromosome conformations have been shown
to deliver highly informative stratifications of complex patient
phenotypes, assist in better disease understanding and target
identifications, and show high concordance with complex genetic and
gene expression profiles. Predictive and prognostic stratifications
developed by OBD on the basis of its proprietary EpiSwitch(TM)
technology already offer significant improvements in patient
stratifications, de-risking of drug discovery and development, and
upgraded regulatory and market protection.
This patent will further extend coverage of OBD's proprietary
technology platform, EpiSwitch(TM), in this important market.
Counterparts to this patent have already been granted in the USA,
Europe, China, Japan, Australia, India, Hong Kong, New Zealand,
Singapore and South Africa.
Christian Hoyer Millar, Chief Executive Officer of Oxford
BioDynamics, commented:
"We are pleased with the addition of this patent covering the
use of our EpiSwitch(TM) technology in the Canadian market. This
patent strengthens our global intellectual property position and
further validates our novel approach to characterising structural
modifications to genome architecture that have a profound effect on
health."
-ENDS-
For further details please contact:
Oxford BioDynamics Plc
Christian Hoyer Millar,
CEO
Paul Stockdale, CFO +44 (0)1865 518910
Shore Capital
Broker and Nominated Adviser
Stephane Auton
Edward Mansfield +44 (0)20 7408 4090
FTI Consulting
Financial Public Relations
Adviser
Brett Pollard
Natalie Garland-Collins +44 (0)20 3727 1000
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a
biotechnology company focused on the discovery and development of
epigenetic biomarkers for use within the pharmaceutical and
biotechnology industry.
The Company's award-winning, proprietary technology platform,
EpiSwitch(TM), aims to accelerate the drug discovery and
development process, improve the success rate of therapeutic
product development and take advantage of the increasing importance
of personalised medicine.
In particular, EpiSwitch(TM) can reduce time to market, failure
rates and the costs at every stage of drug discovery. Additionally,
the technology provides significant insights into disease
mechanisms for drug discovery and product re--positioning
programmes, and enables the personalisation of therapeutics for
patients in the context of challenging pricing environments where
improved clinical outcomes are critical.
Oxford BioDynamics is headquartered in the UK, and listed on the
London Stock Exchange's AIM under the ticker "OBD". For more
information please visit www.oxfordbiodynamics.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDBSGDRSUBBGII
(END) Dow Jones Newswires
July 19, 2018 02:00 ET (06:00 GMT)
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biodynamics (LSE:OBD)
Historical Stock Chart
From May 2023 to May 2024